The advanced validation data, 3D Epitope Mapping, is designed to enhance the efficiency and accuracy of antibody-related selection, empowering scientists with the data they need to advance their ...

Proteintech, a global leader in antibodies and life science solutions, is excited to announce additional product characterization for primary antibody targets on its website ( ptglab.com). The ...

Q4 2024 Earnings Call Transcript March 17, 2025 FibroGen, Inc. reports earnings inline with expectations. Reported EPS is $-0 ...

The advanced validation data, 3D Epitope Mapping, is designed to enhance the efficiency and accuracy of antibody-related selection, empowering scientists with the data they need to advance their work, ...

Achieved Q4 2024 PEMGARDA™ (pemivibart) net product revenue of $13.8 million, representing 48% growth over Q3 2024 net product revenue of $9.3 million; full-year 2024 net product revenue totaled $25.4 ...

Thane Wettig; Interim Chief Executive Officer, Chief Commercial Officer; FibroGen Inc. David Delucia; Vice Presi ...

Not long after the first flu shot was introduced in 1945 by University of Michigan virologist Thomas Francis and his ...

De novo antibody design has been one of the major challenges in AI-based drug discovery, requiring atomic-level precision to ...

New research highlights a critical link between antibodies produced against Epstein-Barr virus (EBV) and the development of ...

The global polyclonal antibody market is poised for significant expansion in the coming decade, driven by increasing ...

Announced sale of FibroGen China to AstraZeneca for a total consideration of approximately $160 millionTransaction expected to close by ...